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Available online 30 July 2016Background: Deﬁnitive diagnosis of visceral leishmaniasis (VL) by demonstrating parasites in
tissue smears or by culture involves invasive procedures, technical expertise and adequate
laboratory facilities. Endemic countries rely mainly on serological tests to diagnose VL. Cur-
rently, the immunochromatographic test incorporating the recombinant K39 antigen (rK39
ICT) is the reference test for rapid diagnosis of VL in the Indian subcontinent. The perfor-
mance of serological tests using rK39 and other promastigote antigens can vary due to differ-
ences in antigen expression, the various hosts and environmental factors. To achieve
elimination of VL, diagnostic accuracy will be necessary for active case detection especially
in those who carry asymptomatic infections. We evaluated the performance of rK39 ICT, en-
zyme linked immunosorbent assay using mixed Leishmania promastigotes from different
Leishmania species (p-ELISA) and indirect ﬂuorescent antibody test (IFAT) utilizing whole
promastigotes from the Leishmania donovani complex for sero-diagnosis of VL in Bangladesh.
Methods: The sensitivity of each serological test was evaluated on 155 patients who were
diagnosed to have VL by microscopy and/or by culture methods. Test speciﬁcities were
calculated on 706 healthy blood donors, 91 diagnostic sera from patients with a febrile ill-
ness and sera from patients positive for malaria (n = 91) and Chagas disease (n = 91).
All statistical calculations were at 95% conﬁdence intervals.
Results: The sensitivities of rK39 ICT, p-ELISA and IFAT were 100%, 86.5% and 92.3%, re-
spectively. All three serological methods had a pooled sensitivity of 82.6%. The speciﬁc-
ities of rK39 ICT, p-ELISA and IFAT from combined control groups were 100%, 93.1% and
99.9%, respectively. The respective positive and negative predictive values of the tests
were both 100% for rK39 ICT, 66.3% and 97.8% for p-ELISA and 99.3% and 98.8% for IFAT.
The p-ELISA showed cross reactivity with 36.3% of sera positive for malaria and 28.6% of
sera positive for Chagas disease while rK39 ICT and IFAT showed no cross reactivity.
Conclusion: This study conﬁrms the efﬁciency of rK39 ICT for rapid diagnosis of VL. The p-
ELISA using mixed promastigote antigens did not perform well as a serological test for VL
in Bangladesh. Due to high sensitivity and speciﬁcity of whole promastigote antigen of
L. donovani complex utilized in IFAT, this test can be considered in combination with
rK39 ICT to conﬁrm VL diagnosis when clinical diagnosis cannot distinguish between
other diseases.
© 2016 The Authors. Published by Elsevier Ltd on behalf of World Federation of Parasitologists.
This is an open access article under the CC BY-NC-ND license
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In the Indian subcontinent, visceral leishmaniasis (VL) is an anthroponotic infection caused by L. donovani and transmitted
by the vector, Phlebotomous argentipes (Sharma and Singh, 2008). Although the total number of cases and mortality due to VL
has declined signiﬁcantly over the last decade, India, Bangladesh and Nepal are yet to reach their elimination target. While
Bangladesh has achieved elimination in 90% of endemic sub-districts (WHO, 2015a), there are 16 sub districts which still
report 1.06 to 18.25 VL cases per 10,000 population per year (Chowdhury et al., 2014). The persistence of endemic foci in
the country, even after extensive control interventions, may give rise to renewed outbreaks and spread to other non-
endemic areas. Therefore, active case detection with reliable diagnostic methods used by ﬁrst-line caregivers in rural commu-
nities should be ensured.
Visceral leishmaniasis is a progressive illness characterized by prolonged fever, enlarged spleen and liver, anaemia, weight
loss and cachexia (Murray et al., 2005; Van Griensven and Diro, 2012). Clinical features of the disease can vary and are often con-
fused with other infections and clinical conditions such as malaria, tuberculosis (TB), leprosy, typhoid fever, hyper reactive ma-
larial splenomegaly (HMS), malnutrition, lymphoma and leukemia (Herwaldt, 1999; Bhargava and Singh, 2012; McGwire and
Satoskar, 2014). Most of these disease conditions especially infectious diseases and malnutrition are common in Bangladesh
(Naheed et al., 2010; Ahmed et al., 2012; Haque et al., 2014; WHO, 2015b). Malaria is endemic in 13 districts of the country,
which overlaps with some districts endemic for VL such as Mymensingh (Haque et al., 2014). Furthermore, misdiagnosis can
occur with patients showing less speciﬁc clinical manifestations. In addition, asymptomatic cases in the community may remain
undetected and may act as potential reservoirs in VL transmission areas (Salotra and Singh, 2006; Bern et al., 2007; Mondal and
Khan, 2011; Ostyn et al., 2011). For active case detection, the recombinant K39 immunochromatographic test (rK39 ICT) offers a
simple, non-invasive and accurate test with increased patient compliance. Reliable tests are also required to estimate actual dis-
ease burden, track disease trends over time, improve diagnosis-treatment algorithms and to verify disease elimination within
communities (Singh and Sundar, 2015). More importantly, serological tests are needed to identify asymptomatic cases of VL
rather than by detection through invasive parasitological procedures which are not likely to be approved for ethical reasons
(Singh and Sundar, 2015).
Although antibody based methods cannot rule out relapses, re-infections and past infections, serological techniques can
help to identify active disease in conjunction with clinical symptoms of suspected individuals (Ostyn et al., 2011;
Srivastava et al., 2013). The rK39 antigen, encoded by a kinesin-like gene found in L. chagasi, can be used either in ICT or
in enzyme linked immunosorbent assays (ELISA) for detecting speciﬁc antibody against the L. donovani complex. Whole
promastigote antigens are used in direct agglutination test (DAT) and indirect ﬂuorescent antibody test (IFAT), while
crude lysates or mixed Leishmania promastigotes are utilized in ELISA (p-ELISA) to detect anti-Leishmania antibodies
(Maia et al., 2012).
In Bangladesh and other endemic areas, those individuals suspected of having VL by clinical examinations, are conﬁrmed
with rK39 ICT before initiating treatment (Ahmed et al., 2014; Ready, 2014). However, patients who have either atypical symp-
toms or are asymptomatic may not be detected, because invasive parasitological methods cannot be justiﬁed (Singh and
Sundar, 2015). Furthermore, the rK39 ICT is approved for use with either serum or plasma only, it is however routinely per-
formed on whole blood in the Indian subcontinent (Cunningham et al., 2012). A study in India shows that rK39 ICT may
show a negative reaction to whole blood with low antibody titre against rK39 antigen even in individuals from endemic
areas with clinical symptoms (Matlashewski et al., 2013). In addition, some cases could be missed because of kit failure due
to either poor storage or improper use of the kit. In cases when the standard parasitological procedure cannot be justiﬁed, a
second serological test using a different form of Leishmania antigen other than rK39, should be considered to conﬁrm the result
of the rK39 ICT. The elimination of VL will require deﬁnitive diagnosis with an accurate non-invasive serological test/s associ-
ated with better patient compliance.
Although, high sensitivity and speciﬁcity of rK39 ICT have been shown (Cunningham et al., 2012; Mathur et al., 2005), anoth-
er study shows that these diagnostic parameters can vary due to extensive diversity of the kinesin gene encoding for the K39
antigen among strains of L. donovani (Bhattacharyya et al., 2013). Host, geographical and environmental factors could also inﬂu-
ence the variation in test results (Cunningham et al., 2012; Bhattacharyya et al., 2013). Test performance using native antigens
derived from L. donovani promastigotes are also shown to be affected by host and topographical factors (Abass et al., 2015). Fur-
thermore, genetic variations in strains of L. donovani in neighbouring India and Nepal (Downing et al., 2012; Imamura et al.,
2016) indicate that molecular divergence of L. donovani strains might exist in Bangladesh. A change in expression of
promastigote molecules including that of the K39 protein could also occur. Consequently, use of a speciﬁc recombinant antigen
in ICT may not detect variants of L. donovani, which might evolve during this elimination program. Furthermore, much of the
research on the sensitivity and speciﬁcity of ICT and ELISA using rK39 antigen (Sarker et al., 2003; Kurkjian et al., 2005; Rouf
et al., 2009) and IFAT using promastigotes of L. enriettii (Muazzam et al., 1992; Alam et al., 1996) were last done in
Bangladesh about seven years ago. Since these serological tests are used to monitor population incidences of VL, regular mon-
itoring and evaluation of serological tests based on these antigens are thus essential to ensure the integrity of their performance
in the ﬁeld. In the present study, we evaluated the efﬁciency of ICT using rK39 antigen, p-ELISA using mixed Leishmania
promastigotes and IFAT utilizing whole promastigotes of the L. donovani complex. Their sensitivity, speciﬁcity and predictive
values in diagnosing VL were assessed.
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2.1. Study design
A cross-sectional study was carried out among VL patients who attended Surya Kanta Kala-azar Research Centre (SKKRC), My-
mensingh, Bangladesh, for diagnosis and treatment from May 2013 to May 2014.
2.2. Study population
Clinically and parasitologically conﬁrmed VL cases (n = 155) and 979 control individuals were included in this study. The con-
trol subjects included healthy blood donors from endemic and non-endemic areas of Bangladesh and Australian patients with
other diseases. The study populations were divided into the following six groups.
2.2.1. Group I (VL cases)
This group comprised of 155 conﬁrmed VL patients who resided in 13 different districts of Bangladesh. Inclusion criteria were:
ages between 2 and 75 years old, either sex, clinical signs and symptoms of VL, no clinical or serological evidence of other acute or
chronic illness and voluntary consent to participate in the study. Female participants who were pregnant or breastfeeding were
excluded from the study.
2.2.2. Group II (endemic healthy control)
This group included 351 healthy blood donors who lived in districts of Mymensingh, Tangail, Jamalpur, Pabna, Sirajganj,
Rajshahi, Panchagarh, Khulna and Gazipur. All of these Bangladeshi districts are known to be endemic for VL (Chowdhury
et al., 2014).
2.2.3. Group III (non-endemic healthy control)
This group had 355 healthy blood donors residing in non-endemic areas of Bangladesh. Those who had lived in the districts
known to be endemic for VL were excluded from this Group.
Inclusion criteria for healthy blood donors (Group II and III) were: ages between 18 and 60 years old, either sex, clinically
healthy, no previous history of VL or PKDL, no clinical or serological evidence of acute or chronic illness and voluntary consent
to participate in the study. Female participants who were pregnant or breastfeeding and menstrual women were excluded
from the study.
2.2.4. Non-endemic diseased control
2.2.4.1. Group IV (patients with febrile illness). This group comprised of 91 diagnostic sera from individuals with a febrile illness ob-
tained from the Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Australia. Australia is non-
endemic for human leishmaniasis.
2.2.4.2. Group V (patients with antibodies to malaria) and Group VI (patients with antibodies to Chagas disease). Stored sera positive for
Plasmodium falciparum (n = 91) and positive for Trypanosoma cruzi (n = 91) were obtained from ICPMR. In addition to calculat-
ing speciﬁcity, sera from Group V and VI were used to show cross-reactivity of these serological tests with other protozoan
infections.
2.3. Conﬁrmative diagnosis of VL
Suspect cases of VL were based on the clinical features of prolonged fever for twoweeks or more, hepatosplenomegaly, anae-
mia, weight loss, weakness and cachexia (Van Griensven and Diro, 2012; Kumar and Nylen, 2012). These patients were admitted
into SKKRC for conﬁrmative diagnosis by parasite detection from blood buffy coats and/or splenic aspirates. The SKKRC is the
only VL research centre in Bangladesh where splenic aspiration has been routinely performed to isolate parasites for research
purposes. It provides facilities for diagnosis and treatment under the National VL Elimination Program. Routine investigations
were carried out to exclude other possible causes of hepatosplenomegaly, fever and anaemia. All cases were screened for malar-
ia using a rapid test kit (SD BIOLINE, Malaria Ag P.f/Pan, Standard Diagnostics, Korea). Individuals with previously mentioned
clinical features and showing positive reactions to the Widal and Mantoux tests were not included in this study. Investigations
such as total blood count, platelet count, haemoglobin levels, bleeding and clotting time were performed and severely anaemic
patients were given blood transfusion. Informed written consent was taken from each participant and from parents or legal
guardians of those b18 years old after they were explained the need for collecting blood and splenic aspirates for research.
An experienced physician was designated to collect splenic aspirates by using a standard universal procedure. A few drops of
aspirate were smeared on glass slides for microscopic examination and the rest was inoculated into Nicolle-Novy-McNeal
(NNN) media (Lumsden and McMillan, 1996) with antibiotics (penicillin and gentamycin) (Square Pharmaceuticals Ltd.,
Dhaka, Bangladesh) and incubated at 24–26 °C. The VL diagnosis was conﬁrmed by the demonstration of Leishmania
amastigotes in Giemsa stained smears and/or presence of promastigotes in cultures prepared from either blood buffy coats
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ration procedure. Conﬁrmation of VL diagnosis in these subjects was done based on parasite detection from smears prepared
from blood buffy coat. Splenic aspiration for parasitological diagnosis on control subjects could not be performed for ethical rea-
sons (Singh et al., 2013). All 155 VL patients were smear positive and only 34 positive cultures could be obtained. These patients
received anti-Leishmania treatment with liposomal amphotericin B (AmBisome) (Gilead, Foster, CA, USA) under the National VL
Elimination Program.2.4. Collection, processing, storage and shipment of blood specimens for Group I, II and III
Individuals included in each study population were assigned a unique identiﬁcation number. A complete medical history
was obtained and a physical examination was done before collection of blood from each subject in groups I, II and III. About
3–4 ml of venous blood was collected from every participant. Blood from Group I was collected in a Vacutainer® containing
lithium-heparin (BD, Franklin Lakes, NJ, USA) when they attended SKKRC. Blood specimens from study Group II and III were
obtained at the Transfusion Medicine Department of Mymensingh Medical College (MMC) and the Transfusion Medicine
Department of Dhaka Medical College (DMC), respectively. Blood donors were routinely examined and screened serologi-
cally for other infections such as malaria, syphilis, human immunodeﬁciency virus (HIV), hepatitis B virus (HBV) and hep-
atitis C virus (HCV) before collecting specimen. An aliquot (3–4 ml) of fresh blood was taken from the donor's transfusion
bag containing anti-coagulant (Citrate, phosphate, dextrose and sodium citrate, USP) and then transferred to a sterile plain
tube.
Plasma and buffy coats were separated from all blood samples after centrifugation at 3000 rpm for 15 min at ambient tem-
perature. Collected plasma specimens were stored at −20 °C until required. Processing, storage and testing of specimens
with rK39 ICT were done at the collection sites except for Group II, which were performed at the Microbiology Department
of MMC. Frozen specimens from Bangladesh were transported in dry ice to Australia for serological testing with p-ELISA and
IFAT.
Sera from Groups IV, V and VI were collected from a serum bank stored at −20 °C in the ICPMR, Australia.2.5. Serological methods
Plasma and sera were tested for anti-Leishmania antibodies using three different serological methods. The tests were per-
formed and interpreted according to the respective manufacturer's instructions.
The rK39 immunochromatographic test (rK39 ICT) (SD Leishmania Ab, BioLine, Standard Diagnostics, INC., Yongin-si, Gyeonggi-
do, Korea) was performed for qualitative detection of anti-Leishmania antibody against L. donovani complex. Twenty microliters of
each sample (plasma or sera) was used for testing. The result was read within 10–15 min. The National VL Elimination Program of
the Peoples' Republic of Bangladesh supplied these kits.
An ELISA kit with mixed Leishmania promastigotes (p-ELISA) (Human Pan-Leishmania Antibody CELISA ELISA kit,
CELLABS PTY LTD, Brookvale, Australia) was used to detect antibodies. Plasma or sera (5 μl) was diluted at 1:400 for testing.
Specimens were considered positive for p-ELISA with optical density (OD) values over 0.22 (cut-off point) which represent-
ed the mean plus three standard deviations (SD) of absorbance obtained from sera and plasma negative for anti-Leishmania
antibodies.
An indirect ﬂuorescent antibody test (IFAT) kit (Leishmania-Spot IF, bioMerieux, Marcy l'Etoile, France) was used to detect an-
tibodies against whole promastigotes of the L. donovani complex. Five microliters of either plasma or sera was diluted at 1:40 for
testing. A positive reaction was recorded when promastigotes showed light green ﬂuorescence of the cytoplasm, membrane and
the ﬂagellum.
The Parasitology Department, ICPMR, Westmead Hospital, Australia provided the p-ELISA and the IFAT kits.2.6. DNA extraction and PCR ampliﬁcation
DNA was extracted from buffy coats obtained from sero-reactive blood donors using QIAamp DNA Mini Kit following the
manufacturer's instructions (QIAGEN, Hilden, Germany). The ribosomal internal transcribed spacer 1 (ITS1) region (300–
350 bp) was ampliﬁed using primers and methodology as previously described (Schonian et al., 2003). Amplicons were visualized
and photographed under UV light in 1.5% agarose gels containing 2% ethidium bromide.2.7. Statistical analysis
Data were analysed by using the statistical software IBM® SPSS version 21 (IBM® SPSS Statistics, Armonk, NY, USA). Sensitiv-
ity, speciﬁcity, positive (PPV) and negative predictive values (NPV) were calculated. Sensitivity was determined on Group I, and
the speciﬁcity was calculated on Group II, III, IV, V and VI. All calculations were estimated at a 95% conﬁdence interval (95% CI) as
described elsewhere (Newcombe, 1998).
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The study was approved by the Bangladesh Medical Research Council (BMRC: # BMRC/NREC/2010–2013/655(1−10) and
Human Research Ethics Committee, Western Sydney Local Health District, Australia (LNR/13/WMEAD/173). Informed written con-
sent was obtained from each participant and from parents or legal guardians of minors before collecting relevant information
(personal details and medical records) and clinical specimens in Bangladesh. The stored sera from Australian patients were ob-
tained from the ICPMR, Westmead Hospital, Australia. All samples were used for research purposes only and the data were anon-
ymously analysed. No competing interest was declared by any of the authors. Funding sources were not involved in designing the
study; in the collection, analysis and interpretation of data; in the writing of the report; nor in the decision to submit the article
for publication.
3. Results
According to medical records and personal interview, all 155 (Group I) were primary VL cases as none of these patients
had previous history of treatment for VL. The respective sensitivity of rK39 ICT, p-ELISA and IFAT were 100%, 86.5% and
92.3% in Group I. The three methods gave a pooled sensitivity of 82.6% (Table 1). All control plasma and sera in Group II,
III, IV, V and VI were non-reactive by rK39 ICT showing speciﬁcity of 100%. The p-ELISA and IFAT showed respective spec-
iﬁcities of 93.1% and 99.9% among these 979 control individuals. Only nine samples from blood donors (ﬁve from Group II
and four from Group III) were positive by p-ELISA. One from Group II was positive by both p-ELISA and IFAT. DNA extracts
from buffy coats of these nine seropositive blood donors were negative for Leishmania DNA by ITS1 PCR. The positive and
negative predictive values of rK39 ICT were both 100%, p-ELISA were 66.3% and 97.8% and IFAT were 99.3% and 98.8%
(Table 2). The p-ELISA showed 36.3% (33/91, 95% CI = 27.1–46.5%) cross reactivity with sera positive for malaria and
28.6% (26/91, 95% CI = 20.3–38.6%) with sera positive for Chagas disease. Neither rK39 ICT nor IFAT showed cross-
reactivity with these 182 sera.
4. Discussion
Demonstration of parasites in either tissue aspirates or buffy coat from peripheral blood is the recognized gold standard meth-
od (Srivastava et al., 2011a; Srividya et al., 2012). Since the sensitivity of parasitological diagnosis from peripheral blood is poor
(Elmahallawy et al., 2014), collection of aspirates from either spleen or bone marrow are therefore the preferred specimen. Test-
ing with splenic aspirates has 93–99% sensitivity, while aspirates from other body sites have a suboptimal sensitivity of 50–86%
(Srivastava et al., 2011a; Chappuis et al., 2007). Apart from being cumbersome, expensive, time consuming and needing skilled
personnel, collection of splenic aspirates has signiﬁcant risks of introducing other infections and causing intra-abdominalTable 1
Sensitivity of three serological methods in 155 cases of conﬁrmed VL.
Serological test Positive Sensitivity 95% CIa
n % %
rK39 ICT 155 100 97.6–100
p-ELISA 134 86.5 80.2–91.0
IFAT 143 92.3 87.0–95.5
rK39 ICT, p-ELISA & IFAT 128 82.6 75.8–87.7
a CI = Conﬁdence interval.
Table 2
Speciﬁcity and predictive values of three serological methods when tested against control sera or plasma.
Serological
test
Speciﬁcity in control groups, % (95% CIa) Predictive value (95% CI)
Group II
(n = 351)
Group III
(n = 355)
Group IV
(n = 91)
Group V
(n = 91)
Group VI
(n = 91)
All groups
(n = 979)
PPVb NPVc
rK39 ICT 100 (99.9–100) 100 (98.9–100) 100 (96–100) 100 (96–100) 100 (96–100) 100 (99.6–100) 100
(97.6–100)
100
(99.6–100)
p-ELISA 98.6
(96.7–99.4)
98.9 (97.1–99.6) 100 (96–100) 63.7
(53.5–72.9)
71.4
(61.4–79.7)
93.1 (91.3–94.5) 66.3
(59.6–72.5)
97.8
(96.6–98.5)
IFAT 99.7 (98.4–100) 100 (98.9–100) 100 (96–100) 100 (96–100) 100 (96–100) 99.9 (99.4–100) 99.3
(96.2–99.9)
98.8
(97.9–99.3)
a CI = Conﬁdence interval.
b PPV = Positive predictive value.
c NPV = Negative predictive value.
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tribute to poor patient compliance (Sundar and Rai, 2002). While molecular detection by PCR is a highly sensitive method
(Srivastava et al., 2011b), it is not available for routine diagnosis of VL in endemic countries. Serological tests can offer a better
alternative for VL diagnosis with the added advantage of detecting anti-Leishmania antibodies when parasites are not found either
by microscopy or by culture (Kilic et al., 2008).
It has been proposed that asymptomatic human cases can act as potential reservoirs for transmission of VL (Ostyn et al.,
2011; Sundar et al., 2008; Mondal et al., 2010). In a recent study in Bangladesh, 29.2% sero-prevalence of asymptomatic in-
fections were detected and 10% of these sero-positive individuals had parasites cultured from blood buffy coats. These indi-
viduals from whom parasites were cultured were also sero-reactive to rK39 ICT, p-ELISA and IFAT (Banu et al., 2016). A
successful elimination program will therefore need to accurately detect and manage asymptomatic individuals who can
carry live Leishmania parasites in their peripheral blood and have the potential of being hidden reservoirs. Since serological
reaction to the rK39 antigen can vary (Cunningham et al., 2012; Bhattacharyya et al., 2013; Abass et al., 2015; Monno et al.,
2009), performance of the rK39 ICT should be monitored regularly for any deviation of sensitivity and speciﬁcity since its ﬁrst
introduction for the regional elimination program. In addition, other serological tests using alternative promastigote antigens
also need to be evaluated as their performance has also been shown to vary with different geographical areas and host im-
mune status (Abass et al., 2015). Studies assessing the efﬁciency of different serological tests have recently been conducted in
India, Nepal and other countries (Cunningham et al., 2012; Abass et al., 2015; Singh et al., 2013; Kumar et al., 2013), but
there is no recent published data on performance of serological tests in Bangladesh. Furthermore, the use of mixed
promastigote antigens derived from various Leishmania species in ELISA for sero-diagnosis of VL have not been assessed in
this country. We chose mixed promastigote antigens in ELISA (p-ELISA) expecting high sensitivity in disease diagnosis. In
this study, we evaluated the rK39 antigen together with different promastigote preparations for testing on VL patients and
blood donors from Bangladesh and control sera from Australian patients.
4.1. rK39 ICT
The sensitivity and speciﬁcity of the rK39 ICT in this study corroborate with results of an earlier Indian study where 100%
sensitivity and 100% speciﬁcity of the test were shown (Mathur et al., 2005). In the Indian subcontinent, other studies show
93–100% sensitivity and 94–100% speciﬁcity (Cunningham et al., 2012; Sarker et al., 2003; Rouf et al., 2009; Singh et al.,
2013; Kumar et al., 2013), while respective lower sensitivity and speciﬁcity are observed in Brazil (61.5%–91% and N95%)
and East Africa (36.8%–87.2% and 90.8%–98%) (Cunningham et al., 2012). A comparison of sensitivities and speciﬁcities of
rK39 ICTs for VL in the Indian subcontinent show that the performance of the test kits of different brands are similar. However,
the Onsite Leishmania Ab (RevB) rapid test demonstrated lower speciﬁcities in India (42%) and Nepal (48.7%) (Kumar et al.,
2013) (Table 3). Lack of published data did not allow us to compare our results with others using the same rK39 ICT kit in
this region.
4.2. p-ELISA
The sensitivity of p-ELISA in our study compared to estimated values by meta-analysis was similar (87%), but the speciﬁcity
was higher than the estimated 77% (Maia et al., 2012). A study from India demonstrated a sensitivity of 100% and speciﬁcity of
87% with ELISA using promastigote antigen from L. infantum (Mandal et al., 2008). Other studies in Bangladesh using the rK39
antigen in ELISA (Kurkjian et al., 2005; Alam et al., 1996) had higher sensitivity and speciﬁcity than the p-ELISA in our study
which used mixed promastigotes from various Leishmania species. This demonstrates that the rK39 antigen has better sensitiv-
ity and speciﬁcity when incorporated either in ELISA or in ICT compared to the mixed promastigote antigens used in the p-
ELISA. Unfortunately, no published data could be found to compare our results using mixed Leishmania promastigotes in
Bangladesh.
4.3. IFAT
Combined sensitivity of 88% and speciﬁcity of 90% with IFAT calculated in the meta-analysis (Maia et al., 2012) were
slightly lower than that found in our study. Although our study showed a similar speciﬁcity to two other studies in
Bangladesh, the sensitivity in our study was however lower than 100% found by these same two studies (Muazzam et al.,
1992; Alam et al., 1996). This variation of test sensitivity between studies in Bangladesh could be due to the different species
used as antigen. Leishmania infantum, which is a species of the L. donovani complex, was used in a commercial kit in our
study. The other two studies used a laboratory preparation of L. enriettii promastigotes which are an enigmatic Leishmania
species of neotropics.
4.4. Cross-reactivity with other protozoan diseases
Several studies demonstrate that promastigote antigens of Leishmania cross-react with sera showing positive reactions
against antigens of malaria and Chagas disease (Romero et al., 2009; Pinedo-Cancino et al., 2013; Toledo-Machado et al.,
2015). In this study, sera positive for malaria and Chagas disease showed considerable cross reactivity in the p-ELISA while
Table 3
Comparison of sensitivities and speciﬁcities of rK39 ICT kits used in the Indian subcontinent.
Country Product Manufacturer Sensitivity n (%)
(95% CI)
Speciﬁcity n (%)
(95% CI)
Reference
India Kala-azar Detect InBios International Inc., Seattle, WA 57 (100)
(93.7–100)
116 (100)
(96.8–100)
Mathur et al.
(2005)
IT-LEISH Diamed AG 221 (99.0–100)
(97.5–99.9)
365 (95–100) Sundar et al.
(2006)
Onsite Leishmania Ab
(RevA) rapid test
CTK Biotech Inc., San Diego, CA, USA 145 (96.7)
(92.4–98.9)
112 (94.1)
(88.3–97.6)
Kumar et al.
(2013)
Onsite Leishmania Ab
(RevB) rapid test
CTK Biotech Inc., San Diego, CA, USA 148 (98.7)
(95.3–99.8)
50 (42.0)
(33.0–51.4)
Kala-azar Detect InBios International Inc., Seattle, WA 149 (99.3)
(96.3–100)
118 (99.2)
(95.4–100)
Diamed-IT LEISH Bio-Rad Laboratories 148 (98.7)
(95.3–99.8)
118 (99.2)
(95.4–100)
Kala-azar Detect InBios International Inc., Seattle, WA 365 (100)
(98.9–100)
421 (94–100)
(94.5–100)
Singh et al.
(2013)
Nepal Onsite Leishmania Ab
(RevA) rapid test
CTK Biotech Inc., San Diego, CA, USA 26 (96.3)
(81.0–99.9)
137 (90.1)
(84.3–94.4)
Kumar et al.
(2013)
Onsite Leishmania Ab
(RevB) rapid test
CTK Biotech Inc., San Diego, CA, USA 27 (100)
(87.0–100)
74 (48.7)
(40.5–56.9)
Kala-azar Detect InBios International Inc., Seattle, WA 26 (96.3)
(81.0–99.9)
143 (94.1)
(89.1–97.3)
Diamed-IT LEISH Bio-Rad Laboratories 26 (96.3)
(81.0–99.9)
141 (92.8)
(87.4–96.3)
ISC (Bangladesh, India
and Nepal)
Diamed-IT LEISH Bio-Rad Laboratories 250 (98.8)
(96.5–99.6)
249 (97.6)
(94.8–98.9)
Cunningham
et al. (2012)
Kala-azar Detect InBios International Inc., Seattle, WA 250 (99.6)
(97.8–99.9)
249 (96.0)
(92.8–97.8)
Onsite Leishmania Ab rapid
test
CTK Biotech Inc. 250 (99.6)
(97.8–99.9)
249 (96.8)
(93.8–98.4)
Bangladesh NAa NA 60 (96.6)
(88.6–99.1)
120 (98.3)
(94.1–99.5)
Sarker et al.
(2003)
NA NA 60 (95)
(86.3–98.3)
60 (98.3)
(91.1–99.7)
Rouf et al. (2009)
SD Leishmania Ab, BioLine Standard Diagnostics, INC. Yongin-si,
Gyeonggi-do, Korea
155 (100)
(97.6–100)
979 (100)
(99.6–100)
Current study
a Information not available.
225S.S. Banu et al. / Parasite Epidemiology and Control 1 (2016) 219–228the rK39 ICT and IFAT did not. These ﬁndings are in agreement with other researchers (Monno et al., 2009; Romero et al., 2009;
Carvalho et al., 2003; Flores-Chavez et al., 2010). Although Chagas disease is not endemic in the Indian subcontinent, the para-
site is a related ﬂagellate with which antibodies generated against this organism cross react with antigens in the p-ELISA.
Nine samples from blood donors in this study showed positive reactions to p-ELISA (n = 9) and IFAT (n = 1) but their blood
buffy coats were tested negative for Leishmania DNA. This was also seen in an earlier study in Bangladesh where none of the
sero-reactive donors were found to have Leishmania DNA in their buffy coats (Huda et al., 2013). These nine sero-positive
blood donors may be at an early stage of an asymptomatic infection when parasites are not detected in the peripheral blood.
Two studies in the Mediterranean region showed that sero-positive blood donors carry L. infantum in their peripheral blood
in low numbers (4.5–11.4%) (le Fichoux et al., 1999; Riera et al., 2004). These ﬁndings indicate that follow up of sero-reactive
donors should be included as part of the elimination program, because clinical disease can occur weeks or months later
(Singh et al., 2002; Das et al., 2011). While this study and a previous study in Bangladesh did not show parasites present in
the blood of donors, routine screening of blood donors for VL should be considered to prevent potential transmission of Leish-
mania through blood transfusions.
As the disease declines in prevalence, serological tests are expected to become the method of choice for early detection and
disease surveillance in the Indian subcontinent. The success of the elimination program has lowered the number of VL cases, this
drop in numbers will in turn affect test efﬁciency and cause a decline in the positive predicative values of diagnostic tests (Singh
and Sundar, 2015). Several studies recommend a combination of antibody based methods for accurate diagnosis of VL to avoid
invasive parasitological procedures, although most of them prefer DAT and rK39 ICT for combined testing (Maia et al., 2012;
Chappuis et al., 2007; Boelaert et al., 2007; ter Horst et al., 2009). The rK39 ICT along with IFAT in this study still show high
sensitivity and speciﬁcity with no cross reactivity against a related ﬂagellate and malaria when using serum or plasma. Further-
more, testing for VL in Bangladesh using whole blood on the rK39 ICT is common practice and has not been evaluated for sen-
sitivity and speciﬁcity so far. Others have also reported false negative results of ICT tests using whole blood (Matlashewski et al.,
2013). We are recommending a combination of two tests using different antigens such as rK39 and promastigotes of L. donovani
complex for IFAT to diagnose VL with declining case numbers. In addition, antibody titres measured by the IFAT can be used to
monitor the patient's long-term recovery (Akin et al., 2009; Proverbio et al., 2014). Although not covered in our study, the
226 S.S. Banu et al. / Parasite Epidemiology and Control 1 (2016) 219–228collection of ﬁlter paper specimens that are mailed back to a reference laboratory for testing will overcome major logistical
problems for further specimen testing (Panteleeff et al., 1999; Smit et al., 2014). Optimizing tests such as the IFAT for screening
of antibodies eluted off ﬁlter paper will widen the choice of testing methods.
5. Conclusion
The performance of the rK39 ICT, currently in use in the elimination program in Bangladesh, remains consistent with earlier
studies and has overall advantages compared with p-ELISA and IFAT. Although p-ELISA shows reasonable sensitivity and spec-
iﬁcity in detecting antibodies to VL, the performance is below that seen with rK39 ICT and IFAT. In addition, antigen containing
mixed Leishmania promastigotes used in p-ELISA cross reacts substantially with malaria and Chagas disease and hence is not
suitable for detecting VL in areas where these diseases are known to be endemic. Although, rK39 ICT still performs well in the
ﬁeld in Bangladesh, regular monitoring for deviation from its expected performance are required as test efﬁciency can vary. Al-
though IFATmay not be ﬁeld friendly, optimizing the IFAT using specimens collected on ﬁlter paperwill allow this test to be used
as an adjunct test with the rK39 ICT. In the later stages of the elimination program, these tests will become more important to
detect asymptomatic infections and to conﬁrm diagnosis especially when clinical features cannot distinguish between other dis-
eases. However, a cost-effective analysis to showwhether serology alone can replace invasive parasitological procedures has yet
to be done.
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